其中，中集醇科是全球最大的罐体、工艺技术与集成系统的智造生产线的企业之一，是国家专精特 新"小巨人"企业，为全球酿造、蒸馏、生物医药等行业领导企业提供设计、制造和集成系统的"交钥 匙"工程解决方案。公司在2024年挂牌后，通过新三板市场定向发行工具融资1.1亿元，缓解公司资金压 力，优化公司财务结构，该公司已于2026年1月报送北交所辅导备案，踏上资本市场进阶之路。 科州药物专注于Ⅰ类抗肿瘤创新药研发，契合新兴产业发展方向，2025年公司实现挂牌，并定向发行融 资6500万元，为创新药研发持续投入提供资本保障。目前，科州药物北交所上市申请已获受理，并进入 问询环节。 业内人士表示，新三板以灵活包容的制度供给，打通中小企业融资"最后一公里"，随着北交所与新三板 协同效应不断增强，市场将持续发挥培育孵化功能，引导金融活水精准流向实体经济，助力更多优质中 小企业借助资本市场实现高质量发展。 经纬科技作为国家专精特新"小巨人"企业，业务聚焦电解铝行业绿色化、智能化解决方案，2025年公司 依托自办发行制度发布定增方案，向郑州天健人才创业投资基金合伙企业(有限合伙)发行股票57.79万 股，融资950万元，用于补充流动 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has experienced a decline, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - As of February 12, 2026, United Imaging Healthcare's stock closed at 127.22 yuan, down 1.0% with a trading volume of 43,100 hands and a transaction value of 549 million yuan [1]. - In the recent three quarters, the company reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit of 1.12 billion yuan, up 66.91% [3]. - The third quarter of 2025 saw a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit of 122 million yuan, up 143.8% [3]. Market Position - United Imaging Healthcare has a total market value of 104.849 billion yuan, ranking second in the medical device industry, with a net asset of 20.805 billion yuan, ranking third [3]. - The company's price-to-earnings ratio (P/E) is 70.2, which is lower than the industry average of 84.83, ranking 66th [3]. - The gross margin stands at 47.02%, slightly below the industry average of 51.01%, ranking 80th [3]. Fund Flow Analysis - On February 12, 2026, the net outflow of major funds was 52.849 million yuan, accounting for 9.62% of the total transaction value, while retail investors saw a net inflow of 37.8691 million yuan, representing 6.89% [1][2]. - Over the past five days, the trend shows consistent net outflows from major funds, indicating a potential bearish sentiment among institutional investors [2]. Analyst Ratings - In the last 90 days, 13 institutions have rated the stock, with 9 buy ratings and 4 hold ratings, and the average target price set at 174.86 yuan [4].

Group 1 - The core viewpoint of the news is that 联影医疗 (688271) has shown significant growth in its financial performance, with a notable increase in revenue and net profit for the first three quarters of 2025 [2] - As of February 9, 2026, the stock price of 联影医疗 closed at 128.92 yuan, reflecting a slight increase of 0.33% [1] - The company reported a main revenue of 88.59 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 27.39% [2] Group 2 - The net profit attributable to shareholders for the same period was 11.2 billion yuan, up 66.91% year-on-year [2] - The company achieved a significant increase in its quarterly performance, with a single-quarter revenue of 28.43 billion yuan in Q3 2025, marking a 75.41% year-on-year growth [2] - The debt ratio of the company stands at 30.08%, indicating a relatively stable financial position [2] Group 3 - The stock has received ratings from 14 institutions in the last 90 days, with 10 buy ratings and 4 hold ratings [2] - The average target price set by institutions for the stock over the past 90 days is 174.86 yuan [2] - The company specializes in providing high-performance medical imaging equipment, radiation therapy products, life science instruments, and medical digitalization and intelligent solutions [2]

Group 1 - The core viewpoint of the news is that 联影医疗 (United Imaging Healthcare) has shown significant financial growth in its recent quarterly report, indicating strong performance in the medical imaging equipment sector [2]. - As of February 4, 2026, the stock price of 联影医疗 closed at 129.95 yuan, reflecting a 1.82% increase with a trading volume of 54,100 hands and a total transaction amount of 695 million yuan [1]. - In the recent funding flow data, the net inflow of main funds was 44.32 million yuan, accounting for 6.38% of the total transaction amount, while retail investors experienced a net outflow of 76.86 million yuan, representing 11.06% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, 联影医疗 reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% year-on-year [2]. - The third quarter of 2025 saw a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit attributable to shareholders of 122 million yuan, reflecting a 143.8% year-on-year growth [2]. - The company has a debt ratio of 30.08% and a gross profit margin of 47.02%, indicating a solid financial position [2].

1月29日的资金流向数据方面，主力资金净流入4102.25万元，占总成交额3.38%，游资资金净流出 3975.89万元，占总成交额3.28%，散户资金净流出126.36万元，占总成交额0.1%。 证券之星消息，截至2026年1月29日收盘，联影医疗(688271)报收于131.1元，上涨2.41%，换手率 1.12%，成交量9.27万手，成交额12.12亿元。 联影医疗2025年三季报显示，前三季度公司主营收入88.59亿元，同比上升27.39%；归母净利润11.2亿 元，同比上升66.91%；扣非净利润10.53亿元，同比上升126.94%；其中2025年第三季度，公司单季度主 营收入28.43亿元，同比上升75.41%；单季度归母净利润1.22亿元，同比上升143.8%；单季度扣非净利 润8761.41万元，同比上升126.24%；负债率30.08%，投资收益6068.47万元，财务费用-4382.33万元，毛 利率47.02%。联影医疗（688271）主营业务：提供高性能医学影像设备、放射治疗产品、生命科学仪 器及医疗数字化、智能化解决方案。 该股最近90天内共有21家机构给出评级，买入评级15家，增 ...

该股最近90天内共有24家机构给出评级，买入评级17家，增持评级7家；过去90天内机构目标均价为 176.35。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： 联影医疗2025年三季报显示，前三季度公司主营收入88.59亿元，同比上升27.39%；归母净利润11.2亿 元，同比上升66.91%；扣非净利润10.53亿元，同比上升126.94%；其中2025年第三季度，公司单季度主 营收入28.43亿元，同比上升75.41%；单季度归母净利润1.22亿元，同比上升143.8%；单季度扣非净利 润8761.41万元，同比上升126.24%；负债率30.08%，投资收益6068.47万元，财务费用-43 ...

1月26日，联影医疗涨0.32%，成交额12.85亿元。两融数据显示，当日联影医疗获融资买入额1.49亿 元，融资偿还1.62亿元，融资净买入-1319.08万元。截至1月26日，联影医疗融资融券余额合计14.70亿 元。 融资方面，联影医疗当日融资买入1.49亿元。当前融资余额14.68亿元，占流通市值的1.33%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，联影医疗1月26日融券偿还3200.00股，融券卖出987.00股，按当日收盘价计算，卖出金额 13.22万元；融券余量1.04万股，融券余额139.46万元，低于近一年10%分位水平，处于低位。 资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 截至9月30日，联影医疗股东户数3.24万，较上期增加96.28%；人均流 ...

证券之星消息，截至2026年1月26日收盘，联影医疗(688271)报收于133.95元，上涨0.32%，换手率 1.16%，成交量9.58万手，成交额12.85亿元。 联影医疗2025年三季报显示，前三季度公司主营收入88.59亿元，同比上升27.39%；归母净利润11.2亿 元，同比上升66.91%；扣非净利润10.53亿元，同比上升126.94%；其中2025年第三季度，公司单季度主 营收入28.43亿元，同比上升75.41%；单季度归母净利润1.22亿元，同比上升143.8%；单季度扣非净利 润8761.41万元，同比上升126.24%；负债率30.08%，投资收益6068.47万元，财务费用-4382.33万元，毛 利率47.02%。联影医疗（688271）主营业务：提供高性能医学影像设备、放射治疗产品、生命科学仪 器及医疗数字化、智能化解决方案。 1月26日的资金流向数据方面，主力资金净流入1.04亿元，占总成交额8.1%，游资资金净流出2917.1万 元，占总成交额2.27%，散户资金净流出7499.27万元，占总成交额5.84%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 ...

Core Viewpoint - The company emphasizes that its stock price in the secondary market is influenced by multiple factors including macroeconomic conditions, industry policies, market sentiment, and investor preferences [1] Group 1: Company Strategy - The company aims to continuously enhance its operational quality and core competitiveness while improving communication with investors to create long-term investment value [1] - As a provider of overall IoT solutions, the company focuses on customer demand and actively expands its market coverage both in breadth and depth [1] Group 2: Business Development - The company is exploring and tapping into emerging business areas, with diversified operations including modules, antennas, ODM, intelligent solutions, and software service platforms [1] - A complete ecosystem has been formed, integrating "hardware + connectivity + platform + application" [1]

证券之星消息，截至2026年1月21日收盘，联影医疗(688271)报收于132.44元，上涨0.39%，换手率 0.96%，成交量7.92万手，成交额10.52亿元。 1月21日的资金流向数据方面，主力资金净流入1217.27万元，占总成交额1.16%，游资资金净流入53.74 万元，占总成交额0.05%，散户资金净流出1271.01万元，占总成交额1.21%。 近5日资金流向一览见下表： | 指标 | 联影医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 1091.51亿元 | 113.47亿元 | 2 127 | | 净资产 | 208.05亿元 | 38.34亿元 | 3 127 | | 净利润 | 11.2亿元 | 2.08亿元 | 5 127 | | 市盈率(动) | 73.08 | 99.95 | 65 127 | | 市净率 | 5.25 | 4.06 | 103 127 | | 毛利率 | 47.02% | 50.94% | 78 127 | | 净利率 | 12.44% | 9.66% | 57 127 | | ROE | 5 ...